Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "legacy"

150 News Found

Jagat Pharma launches isotine eye gummies for enhanced vision support
News | July 31, 2024

Jagat Pharma launches isotine eye gummies for enhanced vision support

These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development


Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India
News | July 19, 2024

Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India

The pooled prevalence of GERD in the Indian population is 15.6 %


USFDA approves next-gen TKI Augtyro for treatment of solid tumors
Drug Approval | June 17, 2024

USFDA approves next-gen TKI Augtyro for treatment of solid tumors

Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors


Neuland unveils refreshed brand identity
News | June 10, 2024

Neuland unveils refreshed brand identity

The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress


Borosil Scientific debuts on stock exchange
News | June 08, 2024

Borosil Scientific debuts on stock exchange

This strategic decision will unlock significant value for our scientific and industrial products business


Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda
Diagnostic Center | June 05, 2024

Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda

The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer


Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause
Diagnostic Center | May 17, 2024

Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause

Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms


Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion
News | May 02, 2024

Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion

First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter


Cipla Health strengthens its play in beauty and personal care
News | April 16, 2024

Cipla Health strengthens its play in beauty and personal care

CHL is strengthening its play in the fast-growing beauty and personal care sector